Monoclonal antibodies Boehringer Ingelheim and Invetx
Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
Search
Social Support
People living with cancer share their perspectives on the importance of social support.
Physical Wellbeing
Resources and videos related to physical wellbeing whilst living with cancer.
Nutrition
People with cancer discuss the benefits she experienced through making dietary changes whilst undergoing cancer treatment.
Purpose: Finding the long-missed meaning
Cancer survivor Missy Pappion is happy at Boehringer Ingelheim after climbing the corporate ladder
Mental Health
Hear the perspectives of people living with cancer on the topic of mental health.
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
Veterinary oncology experts meet in Germany
Veterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, Germany
Advice to Fellow Patients
People living with cancer share their advice for fellow patients, from checking information sources to living in the present moment.
Tips to help you start your patient advocacy journey
Advocating for yourself as a patient can be daunting. Jeff Dunn, President of Union for International Cancer Control (UICC), shares some tips
Ivan Blanarik Therapeutic Area Head Respiratory
Ivan Blanarik, Therapeutic Area Head Respiratory at Boehringer Ingelheim
Ezabenlimab
Ezabenlimab, PD-1 antibody
Dedifferentiated liposarcoma: Life with an ultra rare cancer
For Dan, being diagnosed with dedifferentiated liposarcoma, an ultra rare sarcoma, was life changing, and means he now makes the most of every day.
VSV-GP
VSV-GP
SIRPα antagonist
SIRPα antagonist
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
CD137/FAP agonist
CD137/FAP agonist
B7-H6/CD3 T-Cell Engager
B7-H6/CD3 T-Cell Engager
Sarcoma
Hear from Gary Schwartz, MD, Director of the Case Comprehensive Cancer Center, Cleveland, Ohio, talk about his expert perspectives on sarcoma.
Brigimadlin (BI 907828)
Brigimadlin BI 907828
Brigimadlin
MDM2-p53 antagonist
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager: DLL3/CD3 T-cell engager
Combination Therapy
It’s the smart combination of our cancer cell-directed and immuno-oncology approaches that may offer the greatest benefit for people living with cancer.